US FDA approves Merck's new injectable version of Keytruda
Summary
The U.S. Food and Drug Administration has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that...
The U.S. Food and Drug Administration has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, offering a more convenient option of the widely used cancer immunotherapy, the health regulator said on Friday.
Related Articles
Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield
MRK
PositiveBritain defends investment record as Merck scraps labs over pharma environment
MRK
NegativeBiocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
MRK
Positive